Mangoceuticals, inc. announces pricing of $1,200,000 public offering

Dallas, texas, dec. 15, 2023 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) (“mangorx” or the “company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“grow”) and erectile dysfunction (“ed”) drug (“mango”), today priced its previously announced underwritten public offering of 4,000,000 shares of its common stock, par value $0.0001 per share, at a public offering price of $0.30 per share, for aggregate gross proceeds of $1,200,000 to the company, prior to deducting underwriting discounts and commissions and other offering expenses payable by the company. in addition, the company has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price of $0.30 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.
MGRX Ratings Summary
MGRX Quant Ranking